Cardiovascular and Gastrointestinal Effects of Etoricoxib in the Treatment of Osteoarthritis: A Systematic Review and Network Meta-analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김담 | - |
dc.contributor.author | 조수경 | - |
dc.contributor.author | 남승완 | - |
dc.contributor.author | 권혁희 | - |
dc.contributor.author | 정선영 | - |
dc.contributor.author | 전찬홍 | - |
dc.contributor.author | 임슬기 | - |
dc.contributor.author | 김달호 | - |
dc.contributor.author | 장은진 | - |
dc.contributor.author | 성윤경 | - |
dc.date.accessioned | 2021-08-11T15:44:12Z | - |
dc.date.available | 2021-08-11T15:44:12Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 2093-940X | - |
dc.identifier.issn | 2233-4718 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/8071 | - |
dc.description.abstract | Objective. To estimate the cardiovascular (CV) and gastrointestinal (GI) risks of etoricoxib in the treatment of osteoarthritis (OA) compared to a placebo and other non-steroidal anti-inflammatory drugs (NSAIDs). Methods. A systematic review of randomized, controlled trials (RCTs) of etoricoxib were performed. Bayesian network meta-analysis was used over a duration of 12 weeks. The incidence of CV and GI events for a duration ≥26 weeks were also tabulated and presented using descriptive statistics. Results. From this search, 10 studies were identified. Of these, 6 and 5 RCTs that measured the CV and GI events at 12 weeks were included in meta-analysis. They showed that etoricoxib did not increase the CV events compared to the placebo or NSAIDs during the 12 week period (odds ratio [OR]=0.59 compared to celecoxib, OR=0.89 with ibuprofen, OR=0.70 with placebo, and OR=2.16 with naproxen). The risk of GI events was comparable to that of most comparators, with the exception of naproxen, which had a significantly lower risk of GI events (OR=0.18) during the 12 week period. For a duration ≥26 weeks, the incidence of CV and GI events with etoricoxib increased with increasing duration. Conclusion. Etoricoxib is an alternative short-term treatment option for OA, showing comparable CV and GI complications to other NSAIDs. Nevertheless, further studies will be needed to elucidate the long-term safety of etoricoxib in the treatment of OA. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한류마티스학회 | - |
dc.title | Cardiovascular and Gastrointestinal Effects of Etoricoxib in the Treatment of Osteoarthritis: A Systematic Review and Network Meta-analysis | - |
dc.title.alternative | Cardiovascular and Gastrointestinal Effects of Etoricoxib in the Treatment of Osteoarthritis: A Systematic Review and Network Meta-analysis | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.bibliographicCitation | 대한류마티스학회지, v.24, no.5, pp 293 - 302 | - |
dc.citation.title | 대한류마티스학회지 | - |
dc.citation.volume | 24 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 293 | - |
dc.citation.endPage | 302 | - |
dc.identifier.kciid | ART002276656 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Anti-inflammatory agents | - |
dc.subject.keywordAuthor | non-steroidal | - |
dc.subject.keywordAuthor | Etoricoxib | - |
dc.subject.keywordAuthor | Osteoarthritis | - |
dc.subject.keywordAuthor | Safety | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.